RiboMed Biotechnologies, Inc. (RiboMed) is a molecular diagnostic company providing proprietary epigenetic and genetic biomarker tests for applications in Personalized Medicine, which is the use of information about an individual’s cellular biomarkers (DNA, methylated DNA, RNA, and proteins) to detect and treat disease. The current focus of the Company is on the detection of epigenetic biomarkers (DNA methylation) and genetic biomarkers (DNA mutations or Single Nucleotide Polymorphisms, SNPs) associated with disease initiation, progression and response to drug treatment.

RiboMed provides products and services for disease management and drug development utilizing its proprietary and patented technologies for biomarker detection (Abscription®) and methylated DNA isolation and quantification (MethylMagnet® and MethylMeter®). In February, 2011, the Company expanded to add the RiboMed Clinical Services Laboratory (RCSL, CLIA License # 05D2020043) to offer Abscription-based tests for DNA methylation changes associated with disease diagnosis, progression and drug response. College of American Pathologist (CAP) accreditation is anticipated in early 2012.